This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ZYC300

Eisai Co., Ltd.

Drug Names(s): E7300

Description: ZYC300 is an encapsulated plasmid that contains the tumor antigen cytochrome P450 1B1 (CYP1B1). ZYC300 stimulates the body's T cells to attack cells that express CYP1B1. CYP1B1 is a tumor-specific protein that is found expressed in nearly every major cancer but significantly limited in normal tissue.

Deal Structure: ZYC300 was originally developed by MGI Pharma.

In December 2007, Eisai and MGI Pharma announced that they entered into a definitive merger agreement under which Eisai would acquire all of the outstanding shares of MGI Pharma for US$41.00 per share in an all cash transaction, for a total consideration of approximately $3.9 billion.


ZYC300 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug